Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Cellular Immunotherapy of Canine Cancer.

Addissie S, Klingemann H.

Vet Sci. 2018 Dec 6;5(4). pii: E100. doi: 10.3390/vetsci5040100. Review.

2.

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.

Mazor R, King EM, Onda M, Cuburu N, Addissie S, Crown D, Liu XF, Kishimoto TK, Pastan I.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E733-E742. doi: 10.1073/pnas.1717063115. Epub 2018 Jan 8. Review.

3.

Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin.

Mazor R, Addissie S, Jang Y, Tai CH, Rose J, Hakim F, Pastan I.

AAPS J. 2017 Jan;19(1):117-129. doi: 10.1208/s12248-016-9986-y. Epub 2016 Oct 27.

PMID:
27796910
4.

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.

Mazor R, Onda M, Park D, Addissie S, Xiang L, Zhang J, Hassan R, Pastan I.

Oncotarget. 2016 May 24;7(21):29916-26. doi: 10.18632/oncotarget.9171.

5.

Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.

Mazor R, Crown D, Addissie S, Jang Y, Kaplan G, Pastan I.

Cell Mol Immunol. 2017 May;14(5):432-442. doi: 10.1038/cmi.2015.91. Epub 2015 Oct 19.

6.

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.

Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, Hassan R, Pastan I.

Mol Cancer Ther. 2015 Dec;14(12):2789-96. doi: 10.1158/1535-7163.MCT-15-0532. Epub 2015 Oct 6.

Supplemental Content

Loading ...
Support Center